On October 6, 2022, a new PAD Request for Proposals (RfP) will open for applications. The title of the RfP will be ‘Antivirals for Pandemic Influenza’, and the RfP will support research designed to develop Phase-2 ready novel small-molecule antivirals targeting pandemic influenza.
Proposals should be consistent with at least one of these 4 areas:
- Direct acting antivirals with data demonstrating clear differentiation from currently marketed influenza antiviral products
- Host targeted therapies with data demonstrating clear benefit over currently marketed influenza virus therapeutics
- Compounds that target multiple pathways or mechanisms to reduce the likelihood of resistance emergence
- Compounds demonstrating activity against drug resistant influenza variants
The full call text and guidelines for the call will be available here on the PAD Initiative website on 6 October 2022, and the deadline for applications will be 22 November 2022. Researchers from around the world are encouraged to submit proposals.